Florbetaben PET imaging to detect amyloid beta plaques in Alzheimer's disease: Phase 3 study

Abstract

Progress in research to improve diagnostic accuracy and treatment for Alzheimer disease (AD) depends on the characterization of underlying pathophysiologic mechanisms [ 1 x [1] Vandenberghe, R., Adamczuk, K., Dupont, P., Laere, K.V., and Chetelat, G. Amyloid PET in clinical practice: its place in the multidimensional space of Alzheimer's disease. Neuroimage Clin. 2013; 2: 497–511 Crossref | PubMed | Scopus (62) | Google Scholar See all References ] [1] . With estimates of more than a decade between the onset of β-amyloid deposition and cognitive decline in affected individuals, the opportunity exists to introduce effective disease-modifying regimens [ 2 x [2] McGeer, P.L. and McGeer, E.G. The amyloid cascade-inflammatory hypothesis of Alzheimer disease: implications for therapy. Acta Neuropathol. 2013; 126: 479–497 Crossref | PubMed | Scopus (155) | Google Scholar See all References ] [2] . β-Amyloid imaging may aid this process by facilitating early diagnosis.